Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yafit Segman

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Israel Medical Association Journal : IMAJ|July 12, 2021
Multiple Myeloma with Systemic Amyloidosis: Serum Free Light Chain Dimerization Analysis in the Diagnosis of an Equivocal Case of Plasma Cell DyscrasiaAdrian Duek, Batia Kaplan, Yafit Segman, et al.
Harefuah|March 14, 2023
[PROLONGED POST-COVID-19 ANEMIA]Yafit Segman, Adrian Duek, Yair Goldhechet, et al.
The Israel Medical Association Journal : IMAJ|October 30, 2022
Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kitAdrian Duek, Emmanuel Lellouche, Sharon Ben Baruch, et al.
Journal of Medical Screening|July 12, 2022
Lymphoproliferative disease detected by breast cancer screeningEfrat Luttwak, Yafit Segman, May Saban, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|October 7, 2023
Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimabTal Brosh-Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, et al.
The American Journal of Cardiology|February 24, 2016
Comparison of Triggering and Nontriggering Factors in ST-Segment Elevation Myocardial Infarction and Extent of Coronary Arterial NarrowingJeremy Ben-Shoshan, Yafit Segman-Rosenstveig, Yaron Arbel, et al.
Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Cancer Medicine|February 24, 2024
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximabTali Shafat, Daniel Grupel, Tzvika Porges, et al.
Infectious Diseases and Therapy|December 9, 2024
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter StudyHovav Azuly, Tali Shafat, Daniel Grupel, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Israel Medical Association Journal : IMAJ|July 12, 2021
Multiple Myeloma with Systemic Amyloidosis: Serum Free Light Chain Dimerization Analysis in the Diagnosis of an Equivocal Case of Plasma Cell DyscrasiaAdrian Duek, Batia Kaplan, Yafit Segman, et al.
Harefuah|March 14, 2023
[PROLONGED POST-COVID-19 ANEMIA]Yafit Segman, Adrian Duek, Yair Goldhechet, et al.
The Israel Medical Association Journal : IMAJ|October 30, 2022
Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kitAdrian Duek, Emmanuel Lellouche, Sharon Ben Baruch, et al.
Journal of Medical Screening|July 12, 2022
Lymphoproliferative disease detected by breast cancer screeningEfrat Luttwak, Yafit Segman, May Saban, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|October 7, 2023
Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimabTal Brosh-Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, et al.
The American Journal of Cardiology|February 24, 2016
Comparison of Triggering and Nontriggering Factors in ST-Segment Elevation Myocardial Infarction and Extent of Coronary Arterial NarrowingJeremy Ben-Shoshan, Yafit Segman-Rosenstveig, Yaron Arbel, et al.
Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Cancer Medicine|February 24, 2024
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximabTali Shafat, Daniel Grupel, Tzvika Porges, et al.
Infectious Diseases and Therapy|December 9, 2024
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter StudyHovav Azuly, Tali Shafat, Daniel Grupel, et al.
Pageof 1